| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 78, 1119-1127, Copyright © 1994 by Endocrine Society
ARTICLES |
P Bang, K Brismar and RG Rosenfeld
Department of Pediatrics, Stanford University School of Medicine, California 94305.
Insulin-like growth factor-I (IGF-I) in serum is predominantly bound in a ternary complex, consisting of IGF peptide, IGF-binding protein-3 (IGFBP-3), and an acid-labile subunit, or a binary complex, consisting of IGF peptide and any of the six IGFBPs. In the binary complex, IGF-I is more bioavailable and has a faster turnover rate. Proteolysis of IGFBP-3 may alter the distribution of IGF-I between these complexes by reducing IGFBP-3 affinity for IGF-I and/or acid-labile subunit and may offer an additional mechanism for regulation of IGF availability. In the present study, sera from patients with noninsulin-dependent diabetes mellitus (NIDDM) were found to have significantly higher IGFBP- 3 proteolytic activity than sera from age-matched healthy subjects (188 +/- 12% vs. 104 +/- 6% of a control serum pool; P < 0.001). The mean (+/- SE) of serum IGFBP-3 levels determined by Western ligand blotting was lower in NIDDM patients than in healthy control subjects (61.5 +/- 5% and 79 +/- 5% of a control serum pool, respectively; P < 0.01). However, IGFBP-3 concentrations determined by RIA did not differ. This discrepancy could be explained by IGFBP-3 proteolysis, resulting in IGFBP-3 fragments that are detectable by RIA, but not by Western ligand blotting. Western immunoblotting of sera with or without prior treatment with endoglycosidase-F demonstrated that a glycosylated 29- kilodalton (kDa) IGFBP-3 form with a protein core of 20 kDa was present in sera from healthy controls, and this fragment was increased in NIDDM and term pregnancy sera, suggesting that it is produced by endogenous proteolysis. The presence of the 29-kDa IGFBP-3 proteolytic fragment at about 130-150 kDa after neutral size chromatography of pooled sera may suggest that 29-kDa IGFBP-3 participates in ternary complex formation. Further studies are required to determine whether the avidity of ternary complex formation with the 29-kDa IGFBP-3 fragment is reduced and whether the resulting increased IGF turnover can explain the reduced IGF-I levels (z scores) observed in NIDDM patients compared to healthy subjects (-0.81 +/- 0.32 SD vs. +0.26 +/- 0.17 SD; P < 0.001). Neutral size-chromatography of sera demonstrated that IGFBP-3 protease activity in the approximately 130- to 150-kDa mol wt range is regulated by NIDDM and pregnancy in parallel with that of unfractionated sera.(ABSTRACT TRUNCATED AT 400 WORDS)
This article has been cited by other articles:
 |
|
 |
|
  D. R. Clemmons, M. Sleevi, and W. H. Busby Jr. Recombinant, Nonglycosylated Human Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) Is Degraded Preferentially after Administration to Type II Diabetics, Resulting in Increased Endogenous Glycosylated IGFBP-3 J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6561 - 6568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mesotten, P. J. Wouters, R. P. Peeters, K. V. Hardman, J. M. Holly, R. C. Baxter, and G. Van den Berghe Regulation of the Somatotropic Axis by Intensive Insulin Therapy during Protracted Critical Illness J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3105 - 3113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Heald, K.W. Siddals, W. Fraser, W. Taylor, K. Kaushal, J. Morris, R. J. Young, A. White, and J. M. Gibson Low Circulating Levels of Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Are Closely Associated With the Presence of Macrovascular Disease and Hypertension in Type 2 Diabetes Diabetes, August 1, 2002; 51(8): 2629 - 2636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nygren, C. Carlsson-Skwirut, K. Brismar, A. Thorell, O. Ljungqvist, and P. Bang Insulin infusion increases levels of free IGF-I and IGFBP-3 proteolytic activity in patients after surgery Am J Physiol Endocrinol Metab, October 1, 2001; 281(4): E736 - E741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lassarre, F. Duron, and M. Binoux Use of the Ligand Immunofunctional Assay for Human Insulin-Like Growth Factor (IGF) Binding Protein-3 (IGFBP-3) to Analyze IGFBP-3 Proteolysis and IGF-I Bioavailability in Healthy Adults, GH-Deficient and Acromegalic Patients, and Diabetics J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1942 - 1952. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. F. LAUSZUS, J. G. KLEBE, and A. FLYVBJERG Macrosomia Associated With Maternal Serum Insulin-Like Growth Factor-I and -II in Diabetic Pregnancy Obstet. Gynecol., May 1, 2001; 97(5): 734 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Gravholt, J. Frystyk, A. Flyvbjerg, H. Orskov, and J. S. Christiansen Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E308 - E314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kalmijn, J. A. M. J. L. Janssen, H. A. P. Pols, S. W. J. Lamberts, and M. M. B. Breteler A Prospective Study on Circulating Insulin-Like Growth Factor I (IGF-I), IGF-Binding Proteins, and Cognitive Function in the Elderly J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4551 - 4555. [Abstract] [Full Text]
|
|
|
|
|
|
S. Cianfarani, R. Bonfanti, M. L. M. Bitti, D. Germani, S. Boemi, G. Chiumello, and B. Boscherini Growth and Insulin-Like Growth Factors (IGFs) in Children with Insulin-Dependent Diabetes Mellitus at the Onset of Disease: Evidence for Normal Growth, Age Dependency of the IGF System Alterations, and Presence of a Small (Approximately 18-Kilodalton) IGF-Binding Protein-3 Fragment in Serum J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4162 - 4167. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. R. Devi, D.-H. Yang, R. G. Rosenfeld, and Y. Oh Differential Effects of Insulin-Like Growth Factor (IGF)-Binding Protein-3 and Its Proteolytic Fragments on Ligand Binding, Cell Surface Association, and IGF-I Receptor Signaling Endocrinology, November 1, 2000; 141(11): 4171 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Salahifar, R. C. Baxter, and J. L. Martin Differential Regulation of Insulin-Like Growth Factor-Binding Protein-3 Protease Activity in MCF-7 Breast Cancer Cells by Estrogen and Transforming Growth Factor-{beta}1 Endocrinology, September 1, 2000; 141(9): 3104 - 3110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schuler-Luttmann, G. Monnig, A. Enbergs, H. Schulte, G. Breithardt, G. Assmann, S. Kerber, and A. von Eckardstein Insulin-Like Growth Factor-Binding Protein-3 Is Associated With the Presence and Extent of Coronary Arteriosclerosis Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20 (4): e10 - e15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shinada, A. Akdeniz, S. Panagiotopoulos, G. Jerums, and L. A. Bach Proteolysis of Insulin-Like Growth Factor-Binding Protein-3 Is Increased in Urine from Patients with Diabetic Nephropathy J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1163 - 1169. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. B. M. Janosi, S. M. Firth, J. J. Bond, R. C. Baxter, and P. J. D. Delhanty N-Linked Glycosylation and Sialylation of the Acid-labile Subunit. ROLE IN COMPLEX FORMATION WITH INSULIN-LIKE GROWTH FACTOR (IGF)-BINDING PROTEIN-3 AND THE IGFs J. Biol. Chem., February 26, 1999; 274(9): 5292 - 5298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bang, J. Nygren, C. Carlsson-Skwirut, A. Thorell, and O. Ljungqvist Postoperative Induction of Insulin-Like Growth Factor Binding Protein-3 Proteolytic Activity: Relation to Insulin and Insulin Sensitivity J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2509 - 2515. [Abstract] [Full Text]
|
|
|
|
|
|
A. Nishimura, M. Fujimoto, S. Oguchi, R. D. Fusunyan, R. P. MacDermott, and I. R. Sanderson Short-chain fatty acids regulate IGF-binding protein secretion by intestinal epithelial cells Am J Physiol Endocrinol Metab, July 1, 1998; 275(1): E55 - E63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Skjærbæk, A. Kaal, J. Møller, N. Vahl, J. Weeke, H. Ørskov, and A. Flyvbjerg No Effect of Growth Hormone on Serum Insulin-Like Growth Factor Binding Protein-3 Proteolysis J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1206 - 1210. [Abstract] [Full Text]
|
|
|
|
|
|
B. Kubler, S. Cowell, J. Zapf, and T. Braulke Proteolysis of Insulin-Like Growth Factor Binding Proteins by a Novel 50-Kilodalton Metalloproteinase in Human Pregnancy Serum Endocrinology, April 1, 1998; 139(4): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Twigg and R. C. Baxter Insulin-like Growth Factor (IGF)-binding Protein 5 Forms an Alternative Ternary Complex with IGFs and the Acid-labile Subunit J. Biol. Chem., March 13, 1998; 273(11): 6074 - 6079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yamanaka, E. M. Wilson, R. G. Rosenfeld, and Y. Oh Inhibition of Insulin Receptor Activation by Insulin-like Growth Factor Binding Proteins J. Biol. Chem., December 5, 1997; 272(49): 30729 - 30734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]
|
|
|
|
|
|
P. Bang and P. J. Fielder Human Pregnancy Serum Contains at Least Two Distinct Proteolytic Activities with the Ability To Degrade Insulin-Like Growth Factor Binding Protein-3 Endocrinology, September 1, 1997; 138(9): 3912 - 3917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Flyvbjerg, O. Mogensen, B. Mogensen, and O. S. Nielsen Elevated Serum Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2) and Decreased IGFBP-3 in Epithelial Ovarian Cancer: Correlation with Cancer Antigen 125 and Tumor-Associated Trypsin Inhibitor J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2308 - 2313. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
